|

CB-103 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Glenn J. Hanna1

Indications

  • Recurrent Adenoid Cystic Carcinoma1
  • Metastatic Adenoid Cystic Carcinoma1
  • Adenoid Cystic Carcinoma1
  • Cancer1

Boston, Massachusetts1 trial

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Dana Farber Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.